Corcept’s Grace Study for a new Cushing’s drug; an update

The Corcept Therapeutics “Grace Study”, designed to evaluate the benefits and side effects of a new medication for people with endogenous Cushing’s syndrome, continues full steam ahead.


The company recently announced the availability of new communication materials designed to explain the research details, including eligibility and design information in an easy-to-understand brochure, which you can download here. The booklet will guide you through the process of screening, the steps required to participate, and provide information on a beneficial long-term extension study following completion of the study. If you or someone you know is interested in participating you can view all the participating sites. Corcept told us that If there is not a participating research site available near you, but you are willing to travel, you should contact the site of your choice for more information. Compensation for time and travel may be available. And if you’d like to learn more, this is a link to the study’s website.

Editor’s Note: We believe clinical trials are essential for the advancement of new medications and therapeutics and encourage our readers to learn more and participate in clinical trials as a way to help all patients. We do not endorse or recommend any specific clinical trials or studies.

© 2022, Pituitary World News. All rights reserved.